Table 1.
List of approved HIV RT inhibitors and their regimens in the past decade.
| Antiretroviral drug or regimen | Usage | Trade name | Region | First approval |
|---|---|---|---|---|
| Tenofovir alafenamide (TAF) 25 mg | With other drugs | Vemlidy® | US, EU | 2016-11-10 |
| TAF 25 mg + Emtricitabine (FTC) 200 mg | Pre-exposure prophylaxis | Descovy® | US, EU | 2019-10-03b |
| TAF 25 mg + FTC 200 mg + RPV 25 mg | Complete regimen | Odefsey® | US, EU | 2016-03-01 |
| TAF 25 mg + FTC 200 mg + BIC 50 mg | Complete regimen | Biktarvy® | US, EU | 2018-02-07 |
| TAF 25 mg + FTC 200 mg + DTG 50 mg | Complete regimen | Acriptega®a | USa, India | 2020-12-04a |
| TAF 10 mg + FTC 200 mg + EVG 150 mg + COBI 150 mg | Complete regimen | Genvoya® | US, EU | 2015-11-05 |
| TAF 10 mg + FTC 200 mg + DRV 800 mg + COBI 150 mg | Complete regimen | Symtuza® | US, EU | 2018-07-17 |
| Rilpivirine (RPV) 25 mg | With other drugs | Edurant® | US, EU | 2011-05-20 |
| RPV 25 mg + TDF 300 mg + FTC 200 mg | Complete regimen | Complera® | US, EU | 2011-08-10 |
| RPV 25 mg + DTG 50 mg | Complete regimen | Juluca® | US, EU | 2017-11-21 |
| RPV 300 mg/mL + CAB 200 mg/mL | Complete regimen | Cabenuva® | US, EU | 2021-01-21 |
| Doravirine (DOR) 100 mg | With other drugs | Pifeltro™ | US, EU | 2018-08-30 |
| DOR 100 mg + TDF 300 mg + 3TC 300 mg | Complete regimen | Delstrigo™ | US, EU | 2018-08-30 |
| Elsulfavirine 20 mg | With other drugs | Elpida® | Russia | 2017-06-30 |
| Dapivirine 25 mg vaginal ring | Pre-exposure prophylaxis | – | EU | 2020-07-24 |
| Azvudine 3 mg | With other drugs | Azvudine Tablet | Chinac | 2021-07-21 |
a
The TAF + FTC + DTG regimen is marked as the trade name of Acriptega® in India. The FDA granted the tentative approval of dolutegravir, emtricitabine, and tenofovir alafenamide tablets on 2020-12-04.
b
Descovy® was approved by the FDA for HIV-1 treatment and pre-exposure prophylaxis in 2016 and 2019, respectively.
c
Azvudine was conditionally approved in China.